RECOVERY Trial | Baricitinib in patients admitted to hospital with COVID-19.

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – The Lancet

Invited Commentary: Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality – The Lancet

Related:

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial – medRxiv

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial – The Lancet Respiratory Medicine

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – medRxiv

WHO recommends two new drugs to treat COVID-19 – World Health Organization

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial – The Lancet Respiratory Medicine

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 – New England Journal of Medicine

Commentary on Twitter

New @TheLancet
The largest trial of baricitinib, a JAK-inhibitor drug repurposed via #AI data mining, reduced Covid mortality and the overall reduction consistent with 8 previous RCTs (~20%)https://t.co/5fHDBBvm3Q pic.twitter.com/GDFzcU26H6

— Eric Topol (@EricTopol) July 29, 2022

Under a Creative Commons Attribution (CC BY 4.0) license